How do Lewy bodies form in Lewy body dementia? 

Lewy body dementia is a progressive neurodegenerative condition defined by the presence of abnormal protein aggregates called Lewy bodies within nerve cells. In a clinical context, the formation of these structures represents a major failure in the brain protein management system. While the exact trigger for their development remains a subject of intense research, the biological process involves a specific protein called alpha synuclein transitioning from a functional molecule into a toxic clump that disrupts the essential operations of the neuron. 

As these Lewy bodies accumulate, they interfere with the chemical messengers the brain uses to regulate thinking, movement, and mood. Over time, the affected neurons become unable to function and eventually die, leading to the diverse range of symptoms seen in the clinic. This guide explores the molecular journey of alpha synuclein and the specific ways Lewy bodies damage the brain’s internal infrastructure. 

What we will discuss in this article 

• The normal function of alpha synuclein in the brain 

• The misfolding process and the creation of toxic oligomers 

• How Lewy bodies disrupt neurotransmitter release 

• The impact of protein clumps on the cell energy supply 

• The spread of Lewy body pathology across different brain regions 

• Chronic inflammation and the failure of waste clearance systems 

• emergency guidance for identifying signs of health deterioration 

The role of alpha synuclein 

The primary component of a Lewy body is a protein known as alpha synuclein. In a healthy brain, this protein is abundant, particularly at the ends of nerve cells in structures called presynaptic terminals. 

Under normal conditions, alpha synuclein plays a vital role in regulating the release of neurotransmitters, such as dopamine, which is essential for movement, and acetylcholine, which is critical for memory and learning. It helps manage the supply of synaptic vesicles: the tiny pouches that carry chemical signals between neurons. However, in Lewy body dementia, this once helpful protein begins to change its physical shape, leading to a destructive chain reaction. 

The misfolding and clumping process 

The development of a Lewy body begins when alpha synuclein proteins misfold into an abnormal, sticky shape. 

Once misfolded, these proteins start to stick together, forming small groups called oligomers. Clinical evidence suggests that these early oligomers are actually the most toxic form of the protein, as they can easily move through the cell and interfere with its delicate machinery. As more misfolded proteins join the group, they form long, thread-like structures called fibrils. Eventually, these fibrils tangle together to form the dense, circular masses known as Lewy bodies that clinicians observe in brain tissue samples under a microscope. 

Disruption of cellular function 

Once Lewy bodies have formed, they act as physical and chemical barriers to the survival of the neuron. 

Neurotransmitter failure 

The presence of alpha synuclein clumps prevents the smooth release of neurotransmitters. In the brainstem, this leads to a lack of dopamine, causing the tremors and stiffness typical of Parkinsonism. In the cortex, it disrupts acetylcholine, leading to the profound fluctuations in alertness and memory that define the condition. 

Mitochondrial damage 

Lewy bodies also interfere with mitochondria, the power plants of the cell. By disrupting energy production, the protein clumps leave the neuron vulnerable to oxidative stress and unable to repair itself. When a brain cell can no longer produce enough energy to maintain its basic functions, it triggers a programmed cell death pathway. 

Comparison of protein aggregation 

Feature	Lewy Body	Alzheimer Plaque
Primary Protein	Alpha synuclein	Beta amyloid
Location	Inside the neuron (intracellular)	Outside the neuron (extracellular)
Shape	Dense, circular inclusions	Diffuse, sticky clumps
Primary Impact	Neurotransmitter regulation	Synaptic communication block

Waste clearance failure and inflammation 

In a healthy brain, the waste clearance systems are responsible for identifying and removing misfolded proteins. 

In Lewy body dementia, these systems become overwhelmed or fail. The buildup of toxic alpha synuclein triggers an immune response from the brain microglia cells. While these cells attempt to clear the protein clumps, their overactivation leads to chronic inflammation, which inadvertently damages healthy neurons. Furthermore, there is growing evidence that misfolded alpha synuclein can spread from one cell to another, almost like a slow-moving infection, which explains the progressive spread of symptoms through the brain. 

To summarise 

The formation of Lewy bodies is a complex biological process centred on the misfolding and aggregation of alpha synuclein protein. From its initial role in supporting neurotransmitter release to its final state as a toxic inclusion, this protein transformation drives the neurodegeneration seen in the clinic. By disrupting energy production, chemical signalling, and triggering chronic inflammation, Lewy bodies gradually destroy the brain’s ability to regulate movement and cognition. Understanding this molecular pathway is essential for the development of future therapies aimed at stopping the clumping process before permanent cell loss occurs. 

emergency guidance 

Acute medical issues in Lewy body dementia require immediate clinical attention. Call 999 or seek urgent help if a person experiences a sudden loss of consciousness, a severe fall resulting in injury, or a rapid onset of extreme confusion. Because individuals with this condition are highly sensitive to antipsychotics, seek emergency care immediately if they show signs of a severe adverse reaction: such as high fever, extreme muscle stiffness, or rapid breathing: after starting a new medication. Furthermore, any sudden and profound drowsiness that lasts for hours can indicate an underlying medical emergency like a stroke or severe infection. 

Authority Snapshot 

Dr. Rebecca Fernandez is a UK trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence based approaches such as CBT, ACT, and mindfulness based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well being.